Michael Nordlund, MD
Ophthalmology · Cincinnati, OHNPI 1104853613
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,725 of the $39,998 with a category attached, or 64.3%. 20 manufacturers reported payments, led by Kala Pharmaceuticals, Inc. at 48.7% of the total. Reporting peaked in 2019 at $32,372 and has fallen 99.6% since, to $136 in 2025. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $264.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$19K
- Sun Pharmaceutical Industries Inc.$12K
- Bausch & Lomb Americas Inc.$2K
- Hoya Surgical Optics, Inc$2K
- Carl Zeiss Meditec USA, Inc.$2K
- Alcon$1K
- plus $1K from 14 others
Across 5 payments — averaging $2881.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$14K
What the payments were for
- Consulting fees$3,4509%
- Speaking & faculty fees$25,72564%
- Travel & lodging$6,78317%
- Food & beverage$3,96010%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kala Pharmaceuticals, Inc. | 27 | $19,483 |
| Sun Pharmaceutical Industries Inc. | 27 | $11,780 |
| Bausch & Lomb Americas Inc. | 15 | $2,141 |
| Hoya Surgical Optics, Inc | 1 | $2,000 |
| Carl Zeiss Meditec USA, Inc. | 5 | $1,946 |
| Alcon | 19 | $1,281 |
| AbbVie(2 entities) | 15 | $362 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $177 |
| Lombart Brothers, Inc. | 5 | $140 |
| Dompe US, Inc. | 7 | $139 |
| Novartis | 6 | $112 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $109 |
| Rxsight Inc | 3 | $107 |
| Mallinckrodt Enterprises LLC | 4 | $80 |
| Tarsus Pharmaceuticals, Inc. | 2 | $36 |
| Ivantis, Inc | 1 | $28 |
| Beaver-visitec International, Inc. | 1 | $27 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
| NEW World Medical,inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVELTYS$19,049
- BROMSITE$10,747
- Vivinex Gemetric$2,000
- CIRRUS HD-OCT$1,862
- IOLMaster 700$1,862
- VERACITY SURGICAL$1,862
- VisuMax$1,862
- MIEBO$1,572
- XIIDRA$1,450
- CEQUA$600
- Centurion$155
- IC-8 Apthera IOL$147
- RESTASIS$125
How this compares
$39,998 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 792 | $31,594 |
| RestasisCyclosporine | 29 | $29,992 |
| Ketorolac Tromethamine | 652 | $15,857 |
| XiidraLifitegrast | 12 | $13,423 |
| Loteprednol Etabonate | 27 | $6,155 |
| Ofloxacin | 609 | $5,402 |
| MoxifloxacinMoxifloxacin Hcl | 81 | $1,944 |
| FlarexFluorometholone Acetate | 11 | $1,381 |
| ValacyclovirValacyclovir Hcl | 22 | $1,179 |
| Tobramycin | 40 | $233 |
| Latanoprost | 18 | $183 |
| Timolol Maleate | 16 | $53 |
| Brimonidine Tartrate | 14 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $362 | $29,99229 claims |
| Bausch & Lomb Americas Inc.Xiidra | $2,141 | $13,42312 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $109 | $6,15527 claims |
| Eyevance Pharmaceuticals LLCFlarex | $13 | $1,38111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Cincinnati
- Robert OsherCincinnati$720K
- Christopher RiemannCincinnati$463K
- Anup KhatanaCincinnati$347K
- Michael SnyderCincinnati$216K
- Daniel MillerCincinnati$75K
- Robert SiskCincinnati$46K
- Adam KaufmanCincinnati$19K
- Haroon ChaudhryCincinnati$18K
- Karen KlugoCincinnati$17K
- Clara ChanCincinnati$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.